Document:

SUBLICENSE AND SUPPLY AGREEMENT

THIS  SUBLICENSE  AND  SUPPLY  AGREEMENT  is dated as of  August  4, 2000 and is
entered into between

TRINITY  MEDICAL GROUP USA, INC.  ("TMGUSA"),  a Florida  Corporation,  having a
place of business at 3753 Howard Hughes Parkway, Las Vegas, NV 89109, U.S.A; and

TRINITY ASSETS COMPANY  LIMITED  ("TAC"),  a company  incorporated  in Thailand,
having a place of  business  at 425/129 Soi  Sirijulsawek,  Silom Road,  Bangkok
10500, Thailand.

WITNESSETH:

WHEREAS,  THE IMMUNE  RESPONSE  CORPORATION  (" IRC") and TRINITY  MEDICAL GROUP
COMPANY  LIMITED ("TMG")  entered into the License and  Collaboration  Agreement
dated as of 15 September 1995 (the "License Agreement").

WHEREAS,  TMG  assigned  all of its rights  and  obligations  under the  License
Agreement  to TMGUSA  pursuant  to the terms and  conditions  of the  Assignment
Agreement dated as of 3 August 2000 (the "Assignment Agreement").

WHEREAS,  TMGUSA, Dr. Vina Churdboonchart and TMG entered into the Collaboration
and Supply Agreement dated as of 1 December 1999 (the  "Collaboration and Supply
Agreement").

WHEREAS,  TMGUSA and TAC hereby enter into this Sublicense and Supply  Agreement
dated as of 4 August 2000 (the "Distribution and Supply Agreement").

WHEREAS,  TMGUSA  intends  to  sublicense  some of its  rights  and  obligations
assigned  to it  pursuant  to the  Assignment  Agreement  and supply the Product
purchased  from IRC to TAC in accordance  with the terms and  conditions of this
Agreement.

NOW,  THEREFORE,  in  consideration  of the  foregoing  premises  and the mutual
covenants herein contained, the Parties agree as follows:

ARTICLE 1.        DEFINITION AND INTERPRETATION

Unless otherwise specified in this Agreement, terms used in this Agreement shall
have the same meanings as provided in the License  Agreement between TMG and The
Immune Response Corporation dated September 15, 1995.

<PAGE>

ARTICLE 2.        DEVELOPMENT PROGRAM

2.1      Subcontract of the Development Program
         --------------------------------------

         2.1.1    TMGUSA agrees to  subcontract  the  Development  Program to be
                  performed  by it in the normal  course of its  business to TAC
                  and TAC shall  perform the  Development  Program in compliance
                  with the terms and  conditions  as  specified  in the  License
                  Agreement and shall be in compliance in all material  respects
                  with all  requirements  of laws and  regulations of the United
                  States and the applicable countries of the Territory, together
                  with all good laboratory practices and good clinical practices
                  of the  United  States  and the  applicable  countries  of the
                  Territory.

         2.1.2    The  subcontracting  of  the  Development  Program  shall  not
                  involve  the  transfer of Product  Know-How  to Third  Parties
                  without the prior express written consent of IRC.

         2.1.3    TMGUSA shall supervise the subcontract work.

2.2      Expenses of the Development Program
         -----------------------------------

         2.2.1    In performing the subcontract work of the Development  Program
                  as  specified  in  Article  2.1,  TAC  shall  invoice   TMGUSA
                  appropriate  expenses  associated  with clinical  trials until
                  full regulatory approval of the Product ("Remune") in Thailand
                  is granted.

         2.2.2    Acceptable direct expenses and pay rates include:

                  a)       Principal Investigator Time at US $250 per hour.

                  b)       All travel expenses including air fare at First Class
                           rates, lodging and meals, including incidentals.

                  c)       All  telephone,  fax, and document  delivery  charges
                           between  TAC  and  TMGUSA,   IRC,  Thai  Governmental
                           officials,  Mahidol  University  personnel,  clinical
                           trial  collaborators,   patients,  publications,  and
                           conferences.

                  d)       Associate  Researcher  labor for clinical  trial data
                           statistical analysis at US $125 per hour.

                  e)       CD4 and viral  load  laboratory  assays at US $50 per
                           hour labour or per test result, whichever is greater.

                  f)       All  other  actual   laboratory   fees  and  cost  of
                           necessary  laboratory  equipment  purchases as may be
                           required   in  order  to  carry   out  the  study  in
                           accordance with internationally accepted standards.

                                      -2-
<PAGE>

                  g)       Rental and maintenance  costs of an appropriate study
                           coordinating  center  including  office,   furniture,
                           computers   and  other  data   processing   equipment
                           necessary  at the study  center or at the study  test
                           sites.

2.2.3    Publication Expense Reimbursement
         ---------------------------------

                  h)       TAC  is to  receive  reimbursement  from  TMGUSA  for
                           activities  and expenses as per section 2.2.2 related
                           to each instance of publication of scientific results
                           of the Product in peer reviewed scientific  journals.
                           Such reimbursement is to be made for all publications
                           submitted  prior to full  regulatory  approval of the
                           Product in Thailand. Example publications include but
                           are not  limited to the  Journal of AIDS,  Journal of
                           Human  Virology,  and the  New  England  Journals  of
                           Medicine.

                  i)       TAC is to receive  reimbursement  for direct expenses
                           from  TMGUSA  as per  section  2.2.2  for  each  oral
                           presentation  of Product study results in front of an
                           international   scientific   conference   where  such
                           conference  has more than 50 attendees from different
                           organizations.  Such  award  is to be  made  for  all
                           presentations  submitted  prior  to  full  regulatory
                           approval  of the  Product in  Thailand.  Evidence  of
                           presentation  is a copy of the program that  included
                           the presentation's abstract.

                  j)       TAC is to receive  reimbursement  for direct expenses
                           from  TMGUSA as per  section  2.2.2  for each  poster
                           presentation   of   Product   study   results  in  an
                           AIDS-related   international  scientific  conference.
                           Such  award  is  to be  made  for  all  presentations
                           submitted  prior to full  regulatory  approval of the
                           Product in Thailand.

ARTICLE 3.        SUBLICENSES

3.1      Sublicense Rights
         -----------------

         TMGUSA  hereby  grants to TAC an exclusive  sublicense in the Territory
         for the marketing,  promoting,  selling and  distributing  the Product.
         This  sublicense  shall be subject  to the  provisions  of the  License
         Agreement.

3.2      Rights to Market  and Sell the  Product in other  countries  other than
         -----------------------------------------------------------------------
         Thailand
         --------

         In the event  that TAC,  TMGUSA or any of its  Affiliates  secures  the
         required  marketing  approval  for  the  Product  in a  country  in the
         Territory  (other than Thailand),  the profits from the sale of Product
         in such country shall be divided  equally  between  TMGUSA,  TAC or the
         relevant Affiliate.

3.3      Supports for the  Manufacturing  and other related  Facilities  for the
         -----------------------------------------------------------------------
         Marketing,  Promoting,  Selling  and  Distribution  of the  Product  in
         -----------------------------------------------------------------------
         Thailand
         --------

         TMGUSA  agrees to  provide  support  to TAC (in the form and  substance
         satisfactory  to

                                      -3-
<PAGE>

         both parties) for the  warehousing,  transportation,  production of any
         related capital assets, plant equipment, land purchases or leases which
         are necessary for the marketing, promoting, selling and distribution of
         the Product in Thailand.

ARTICLE 4.        PRODUCT SUPPLY

4.1      Purchase and Sale of Products
         -----------------------------

         TMGUSA  agrees to sell the  Product  to TAC at the  price  equal to the
         minimum of US $75 above the TMGUSA's  cost of the Product for each [100
         micrograms dose] purchased.

4.2      Adjustment of the Purchase Price
         --------------------------------

         If the Product is commercially  sold or distributed in the Territory in
         other than 100 microgram  doses,  the parties  shall  negotiate in good
         faith a mutually acceptable adjustment to the purchase price.

4.3      Payment Terms
         -------------

         TMGUSA  shall  extend  credit to TAC for the  Product  orders  that are
         consigned  to  distributor(s),  provided  that  TAC is able to  provide
         sufficient  cash at the  time of  delivery  to  cover  the  cost of the
         Product  (including cost of goods from the  manufacturer,  shipping and
         direct expenses).

         TAC shall pay the remaining  balance  within 90 days after the shipment
of the Product.

ARTICLE 5.        CONFIDENTIALITY

5.1      Nondisclosure Obligations
         -------------------------

         Except as otherwise  provided in this Article 5, during the term of the
         Agreement  and for a period  of five (5)  years  thereafter,  TAC shall
         maintain in  confidence  and use only for purposes of the Agreement all
         information  and data,  of any type  whatsoever,  (a)  disclosed by IRC
         and/or TMGUSA and identified as, or acknowledged  to be,  confidential,
         or (b)  resulting  from the  Development  Program  or  relating  to the
         Product (the "Confidential Information").

5.2      Permitted Disclosures
         ---------------------

         To the extent it is reasonably  necessary or appropriate to fulfill its
         obligations  under this  Agreement,  TAC may disclose (a)  Confidential
         Information  it is  otherwise  obligated  under  this  Article 5 not to
         disclose to its  employees,  directors,  officers or any other  persons
         related  to the  Development  Program  on a  need-to-know  basis on the
         condition  that such  persons  agree in  writing,  or are  subject to a
         written  Institution  policy,  to  keep  the  Confidential  Information
         confidential for the same time periods and to the same extent as TAC is
         required  to keep the  Confidential  Information  confidential  and (b)

                                      -4-
<PAGE>

         Confidential   Information   to   governmental   or  other   regulatory
         authorities  to  the  extent  that  such   disclosure  is  required  by
         applicable law, regulation or court order,  provided that TAC shall, to
         the extent  practicable,  give advance written notice to TMGUSA thereof
         and sufficient  opportunity to object to such  disclosure or to request
         upon discover of any unauthorized use or disclosure of the Confidential
         Information.

         The obligation not to disclose or use  Confidential  Information  shall
         not apply to the extent that TAC can demonstrate that (i) the disclosed
         information was public knowledge at the time of such disclosure by TAC,
         or  thereafter  became  public  knowledge,  other  than as a result  of
         actions of TAC, its directors, officers, employees or any other persons
         related to the  Development  Program,  in  violation  hereof,  (ii) the
         disclosed information was rightfully known by TAC or its affiliates (as
         shown by its written  records)  prior to the date of  disclosure to TAC
         hereunder;  or (iii) the disclosed  information was disclosed to TAC or
         its affiliates on an unrestricted  basis from a source unrelated to any
         party to the Agreement and not under a duty of  confidentiality  to IRC
         or TMGUSA.

5.3      Publication
         ------------

         Subject to the provisions of Sections 5.1 and 5.2 above, TAC shall have
         the right to publish the results of the Development Program;  provided,
         however,  that TAC shall  provide  TMGUSA  and IRC the  opportunity  to
         review  any  proposed  manuscripts  or any  other  proposed  disclosure
         describing  such  results  not less than sixty (60) days prior to their
         proposed  submission  for  publication  or other  proposed  disclosure.
         TMGUSA or IRC shall  have the  right to  require  the delay of any such
         publication  or  disclosure  for a period of up to ninety  (90) days to
         permit to prepare and file such patent  applications as it believes are
         necessary or desirable to protect any  patentable  subject matter to be
         disclosed in such publication or other disclosure.  TMGUSA or IRC shall
         also have the right to  require  the delay of any such  publication  or
         disclosure until such time as TMGUSA or IRC has filed such results with
         the FDA.

5.4      Terms and Conditions of the Agreement
         -------------------------------------

         TAC and  TMGUSA  shall  not  disclose  any terms or  conditions  of the
         Agreement  to any Third Party  without  the prior  consent of the other
         parry, except as required by applicable law or to Persons with whom TAC
         or  TMGUSA  has  entered  into or  proposes  to enter  into a  business
         relationship,  provided that such Persons shall enter into the required
         confidentiality agreement.

ARTICLE 6.        MISCELLANEOUS

6.1      Notices
         --------

         Any consent, notice or report required or permitted to be given or made
         under  the  Agreement  by a party to the  other  shall  be in  writing,
         delivered  personally  or  by  facsimile  (and  promptly  confirmed  by
         personal delivery, air mail or internationally-recognized  courier) air
         mail or  internationally-recognized  courier,  postage  prepaid  (where

                                      -5-
<PAGE>

         applicable),  addressed  to the other  party at its  address  indicated
         furnished in writing to the addressor and (except as otherwise provided
         in the Agreement) shall be effective upon receipt by the addressee.

         If to TMGUSA:                 Trinity Medical Group USA, Inc.
                                       3753 Howard Hughes Parkway
                                       Las Vegas, NV 89109
                                       U. S. A.

                                       Attention:  Mr. James S. Namnarth, Ph.D.
                                                   Chief Operating Officer

         If to TAC:                    Trinity Assets Company Limited
                                       425/l29 Soi Sirijulsawek
                                       Silom Road
                                       Bangkok 10500, Thailand

                                       Attention:   Mr. Inthanom Churdboonchart
                                                    Director

6.2      Applicable Law
         ---------------

         This  Agreement  shall be governed by and construed in accordance  with
         the laws of the United States and the State of Nevada.

6.3      Entire Agreement
         -----------------

         The Agreement  between TMGUSA and TAC,  together with their  respective
         exhibits,  contain the entire understanding of the parties with respect
         to the subject  matter  hereof.  All express or implied  agreements and
         understandings,  either oral or written,  heretofore made are expressly
         superseded by the Agreement. This Agreement may be amended, or any term
         hereof  modified,  only by a written  instrument  duly executed by both
         parties.

6.4      Headings
         ---------

         The captions to the several Articles and Sections hereof are not a part
         of the Agreement, but are merely guides or labels to assist in locating
         and reading the several Articles and Sections of this Agreement.

6.5      Independent Contractors
         -----------------------

         It is  expressly  agreed  that  TMGUSA  and TAC  shall  be  independent
         contractors and that the relationship between the two parties shall not
         constitute a partnership,  joint venture or agency.  Neither TMGUSA nor
         TAC shall have the authority to make any statements, representations or
         commitments of any kind, or to take any action,  which shall be binding
         on the other, without the prior consent of the other party to do so.

                                      -6-
<PAGE>

6.6      Waiver
         -------

         The waiver by either  party of any right  hereunder  or the  failure to
         perform or of a breach by the other  party shall not be deemed a waiver
         of any other right  hereunder or of any other breach or failure by said
         other party whether of a similar nature or otherwise.

IN WITNESS WHEREOF,  the parties have executed this Agreement as of the date set
forth above.

For and on behalf of TRINITY MEDICAL GROUP USA, INC.

By:
/s/ Vina Churdboonchart                   /s/ James Namnath
------------------------------------      --------------------------------------

For and on behalf of
TRINITY ASSETS COMPANY LIMITED

By:
/s/ Inthanom Churdboonchart               /s/ Orranart Churdboonchart
------------------------------------      --------------------------------------

                                      -7-SUPPLEMENT TO THE SUBLICENSE AND SUPPLY AGREEMENT

THIS SUPPLEMENTAL AGREEMENT is dated 5 August 2000 and is entered into between

TRINITY  MEDICAL  GROUP USA INC. (" TMGUSA"),  a Florida  Corporation,  having a
place of business at 3753 Howard Hughes Parkway,  Las Vegas, NV 89109, U. S. A.;
and

TRINITY ASSETS COMPANY  LIMITED (" TAC"),  a company  incorporated  in Thailand,
having a place of  business  at 425/129 Soi  Sirijulsawek,  Silom Road,  Bangkok
10500, Thailand

WITNESSETH:

WHEREAS,  THE TRINITY  MEDICAL  GROUP USA,  INC. (" TMGUSA") and TRINITY  ASSETS
COMPANY  LIMITED (" TAC")  entered  into a  Sublicense  and Supply  Agreement ("
Sublicense and Supply Agreement") dated August 4,2000, both parties hereby agree
to amend the said Sublicense and Supply Agreement under the terms and conditions
of this agreement.

NOW, THEREFORE, the parties agree as follows:

The following shall be added as Clauses 3.3 and 3.4 of the Sublicense and Supply
Agreement:

Quote

3.3.     Manufacturing Rights
         --------------------

         TMGUSA  hereby  grants  to TAC  manufacturing  rights  to Remune in the
         Territory (Thailand and 9 other countries).

3.4      Supports for the  Manufacturing  and other related  Facilities  for the
         -----------------------------------------------------------------------
         Marketing,  Promoting,  Selling  and  Distribution  of the  Product  in
         -----------------------------------------------------------------------
         Thailand
         --------

         TMGUSA  agrees to provide  supports  to TAC (in the form and  substance
         satisfactory  to both  parties)  for the  warehousing,  transportation,
         production  of  any  related  capital  assets,  plant  equipment,  land
         purchases or leases which are necessary for the  marketing,  promoting,
         selling and distribution of the Product in Thailand.

Unquote

         Except as otherwise specified in this supplement,  all other conditions
         and agreements in the Sublicense and Supply  Agreement  remain the same
         and in full force and effect.

<PAGE>

         IN WITNESS WHEREOF,  the parties have executed this Agreement as of the
date set forth above.

         For and on behalf of TRINITY MEDICAL GROUP USA, INC.

         By:

         /s/ James Namnath, CEO               /s/ Vina Churdboonchart, President
         --------------------------------     ----------------------------------

         For and on behalf of
         TRINITY ASSETS COMPANY LIMITED

         By:

         /s/ Inthanom Churdboonchart          /s/ Orranart Churdboonchart
         --------------------------------     -------------------------------
         Inthanom Churdboonchart              Orranart Churdboonchart

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00016-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00016-of-00352.parquet"}]]